As of September 1, 2025, Shionogi & Co., Ltd. completed the acquisition of all shares of Torii Pharmaceutical Co., Ltd., making it a wholly-owned subsidiary.<\/p>\n","protected":false},"comment_status":"open","ping_status":"closed","template":"","meta":{"Ticker":"","DATE":"","longName":"","company_name_ja":"","fullTimeEmployees":0,"address":"","phone":"","website":"","industry":"","sector":"","regularMarketPrice":0,"financialCurrency":"","marketCap":0,"fiftyTwoWeekLow":0,"fiftyTwoWeekHigh":0,"epsTrailingTwelveMonths":0,"epsForward":0,"bookValue":0,"totalRevenue":0,"OperatingIncome":0,"operatingMargins":0,"NetIncome":0,"profitMargins":0,"ebitda":0,"trailingPE":0,"forwardPE":0,"priceToBook":0,"returnOnEquity":0,"recommendationMean":0,"recommendationKey":"","targetMeanPrice":0,"numberOfAnalystOpinions":0,"analyst_earnings_data":"","dividendRate":0,"dividendYield":0,"payoutRatio":0,"totalEsg":0,"environmentScore":0,"socialScore":0,"governanceScore":0,"title":"","providerPublishTime":"","link":"","longBusinessSummary":"","longBusinessSummary_ja":"","quarterly_revenue":0,"quarterly_net_income":0,"quarterly_operating_profit":0,"enterprise_value":0,"company_officer_1_name":"","company_officer_1_title":"","company_officer_2_name":"","company_officer_2_title":"","company_officer_3_name":"","company_officer_3_title":"","company_officer_4_name":"","company_officer_4_title":"","company_officer_5_name":"","company_officer_5_title":"","company_officers_update_time":"","get_dividend_history_year1":0,"get_dividend_history_year2":0,"get_dividend_history_year3":0,"get_dividend_history_year4":0,"get_dividend_history_year5":0,"get_dividend_history_year6":0,"get_dividend_history_year7":0,"get_dividend_history_year8":0,"get_dividend_history_year9":0,"get_dividend_history_year10":0,"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"jir_stock_code":"4507","jir_company_name":"Shionogi & Co., Ltd.","jir_importance":"\u2605\u2605\u2605\u2605\u2606","jir_publication_date":"2025-09-01","jir_source_link":"https:\/\/japanir.jp\/wp-content\/uploads\/2026\/01\/4507-20250901-01.pdf","jir_short_summary":"As of September 1, 2025, Shionogi & Co., Ltd. completed the acquisition of all shares of Torii Pharmaceutical Co., Ltd., making it a wholly-owned subsidiary.","jir_summary":"### Overview of the M&A\nShionogi & Co., Ltd. commenced a tender offer for shares of Torii Pharmaceutical Co., Ltd. on May 8, 2025, acquiring 39.05% of the shares as of June 25, 2025, and made it an equity-method affiliate. Subsequently, on August 8, 2025, a share consolidation was executed, and on September 1, 2025, Torii Pharmaceutical completed a treasury stock acquisition by acquiring shares held by Japan Tobacco Inc., thereby making Torii Pharmaceutical a wholly-owned subsidiary.\n\n### Future Outlook and Impact\nThe impact on consolidated financial results due to the wholly-owned subsidiary acquisition is currently being examined, and will be promptly disclosed as necessary. Torii Pharmaceutical primarily engages in pharmaceutical manufacturing and sales, with sales and profits showing an increasing trend over the past three years.","jir_financial_highlights":"Number of Shares Acquired: 10,977,091 shares (39.05% ownership acquired (as of June 25, 2025))\nDate of Wholly-Owned Subsidiary Acquisition: 2025-09-01 (Unknown)\nTorii Pharmaceutical Net Sales (Fiscal Year Ending December 2024): 60,426 million JPY (Year-over-Year increase (54,638 million JPY \u2192 60,426 million JPY))\nTorii Pharmaceutical Operating Income (Fiscal Year Ending December 2024): 6,798 million JPY (Year-over-Year increase (5,035 million JPY \u2192 6,798 million JPY))\nTorii Pharmaceutical Net Income Attributable to Owners of Parent (Fiscal Year Ending December 2024): 5,042 million JPY (Year-over-Year increase (4,119 million JPY \u2192 5,042 million JPY))","jir_category":"","jir_hashtags":"#ShionogiCoLtd, #M&A, #ToriiPharmaceutical, #JapaneseStocks","jir_key_figures":"Date of Wholly-Owned Subsidiary Acquisition: 2025-09-01\nNumber of Shares Acquired: 10,977,091 shares (39.05%, as of June 25, 2025)\nTorii Pharmaceutical Net Sales (Fiscal Year Ending December 2024): 60,426 million JPY","jir_meta_title":"Shionogi & Co., Ltd. Completes Wholly-Owned Subsidiary Acquisition of Torii Pharmaceutical - Share Acquisition Completed as of September 1, 2025","jir_meta_description":"Shionogi & Co., Ltd. has completed making Torii Pharmaceutical Co., Ltd. its wholly-owned subsidiary as of September 1, 2025. Acquired 39.05% of shares as of June 25, 2025, and after share consolidation and treasury stock acquisition, owns all shares.","jir_og_title":"Shionogi & Co., Ltd. Completes Wholly-Owned Subsidiary Acquisition of Torii Pharmaceutical (September 1, 2025)","jir_og_description":"Shionogi & Co., Ltd. has acquired all shares of Torii Pharmaceutical Co., Ltd., completing its status as a wholly-owned subsidiary. The impact on future consolidated financial results is under review.","jir_og_image_url":"\/assets\/og\/company-m_and_a_alliance.jpg","jir_chart_data_collection":"[]","ir_related_company":6919,"ir_release_date":"","ir_type":"","ir_is_new":false,"ir_document_url":"","jir_ir_type":"m_and_a_alliance","footnotes":""},"sector":[],"importance":[],"class_list":["post-20298","ir_release","type-ir_release","status-publish","hentry"],"yoast_head":"\n